Financial Highlights

• Revenue Growth: Metropolis Healthcare Limited reported a 12% YoY growth in revenue for FY2024-25, with a 10% YoY growth in Q4FY25.
• PAT Growth: The company achieved a 14% YoY growth in Profit After Tax (PAT) for FY2024-25, with a 24% YoY growth in Normalized PAT.
• Segment Performance: TruHealth revenue grew 24% YoY, while Specialty diagnostics grew 13% YoY in FY2024-25.
• Geographic Expansion: Metropolis expanded to 750+ towns in FY2024-25, with the addition of 29 new labs and 400 centres.

Key Financial Metrics

• Revenue from Operations: INR 1,331 Cr (FY2024-25), INR 345 Cr (Q4FY25)
• Adj. EBITDA: INR 325 Cr (FY2024-25), INR 84 Cr (Q4FY25)
• Profit After Tax: INR 146 Cr (FY2024-25), INR 29 Cr (Q4FY25)

What This Means for You

• Be cautious of the company's declining PAT margin in Q4FY25, which may impact future profitability.
• Consider the potential risks of the company's aggressive expansion and acquisition strategy, which may lead to increased debt and operational challenges.